At AstraZeneca, our ambition is to transform outcomes for patients with hematologic malignancies and related hematology conditions. We aim to reset standards of care by advancing innovative therapies across a broad pipeline inclusive of assets, including bispecific T-cell engagers (TCEs), antibody-drug conjugates (ADCs), and other emerging modalities.

Reporting into the VP, Global Head, Hematology Franchise & Cell Therapy and sitting on the Leadership Team, as Head of Early Assets, Hematology, you will operate at the commercial–R&D interface to shape our early hematology pipeline from preclinical through early clinical development—ensuring clear line-of-sight to patient impact and long-term commercial value across modalities and disease segments.

You will partner closely with Oncology R&D, Global Product Teams, Business Development, Medical, Market Access/Pricing, Finance, and priority markets to build winning target product profiles, inform clinical plans, and define ea...